Who do we exclude if we only consider subjects with excellent quality spirometry?Analysis of UK Biobank longitudinal data.

A. Lenoir (London, United Kingdom), J. Potts (London, United Kingdom), J. Quint (London, United Kingdom), D. Jarvis (London, United Kingdom)

Source: International Congress 2019 – Tuberculosis epidemiology, bronchiectasis, other infections and spirometry
Session: Tuberculosis epidemiology, bronchiectasis, other infections and spirometry
Session type: Thematic Poster
Number: 2806
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Lenoir (London, United Kingdom), J. Potts (London, United Kingdom), J. Quint (London, United Kingdom), D. Jarvis (London, United Kingdom). Who do we exclude if we only consider subjects with excellent quality spirometry?Analysis of UK Biobank longitudinal data.. 2806

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Evaluation of factors to consider prior to adjustment of biologic quality control ranges using data from a large multi-centre clinical trial
Source: Annual Congress 2009 - Quality control in lung function and new developments
Year: 2009


Real-world effects of lumacaftor/ivacaftor (LUM/IVA) in people with cystic fibrosis (pwCF): interim results of a long-term safety study using US CF Foundation Patient Registry (CFFPR) data
Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis
Year: 2021


Real-world effects of tezacaftor/ivacaftor (TEZ/IVA) in people with cystic fibrosis (pwCF): interim results of a long-term safety study using US CF Foundation Patient Registry (CFFPR) data
Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis
Year: 2021


Multi-centre research: The experience of a UK, Danish and Dutch qualitative study exploring the meaning of COPD and its exacerbations to patients
Source: Eur Respir J 2003; 22: Suppl. 45, 66s
Year: 2003

Registries: roles, objectives and registry data study outcomes
Source: Eur Respir Monogr 2019; 85: 150-158
Year: 2019


Asthma quality of life in clinical trials - can we combine data from different countries?
Source: Eur Respir J 2001; 18: Suppl. 33, 4s
Year: 2001

Health economics of COPD: First results of the new German COSYCONET cohort compared to population-based controls from KORA
Source: International Congress 2014 – Highlights in respiratory epidemiology
Year: 2014

Asthma severity, poor control, co-morbidities and prior resource use determined omalizumab prescriptions in a nested case-control study with US claims data
Source: International Congress 2015 – Clincal aspects of asthma: monitoring and mechanisms
Year: 2015


Quality of spirometries to assess possible COPD in current smokers. Results from an ongoing study in general practice in Switzerland
Source: Eur Respir J 2005; 26: Suppl. 49, 55s
Year: 2005

Clinical characteristics, mortality rates and causes of death in non-exacerbating COPD patients. A longitudinal cohort analysis of UK primary care data.
Source: Virtual Congress 2021 – New evidence from longitudinal COPD cohorts and other key studies
Year: 2021



Hayfever has a significant detrimental impact on national exam performance in UK teenagers: case control study
Source: Eur Respir J 2005; 26: Suppl. 49, 134s
Year: 2005

Evaluation of a method for establishing biologic quality control ranges from the first 20 acceptable test sessions in a large multi-center study
Source: Annual Congress 2009 - Quality control in lung function and new developments
Year: 2009


Does one year change in quality of life predict the mortality in patients with COPD?: Prospective cohort study
Source: Annual Congress 2013 –Quality of life and respiratory symptoms in primary care COPD populations
Year: 2013

Introducing the UK Biobank cohort study – what‘s in it for respiratory disease?
Source: Eur Respir J 2005; 26: Suppl. 49, 597s
Year: 2005

LATE-BREAKING ABSTRACT: One-year assessment of asthma control and quality of life in Europe: The liaison study (international cross-sectional and longitudinal assessment on asthma control)
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015


The primary care routine data registry BeoNet: First pilot phase results for COPD research
Source: International Congress 2015 – Patient health gains related to the economic effectiveness of disease management programmes
Year: 2015

A cross-sectional study on the use of information technology among people with COPD, in Sweden
Source: Virtual Congress 2021 – Respiratory physiotherapy: e-health, activities of daily living and measurement properties of instruments
Year: 2021


Air pollution, lung function and COPD: results from the population-based UK Biobank study
Source: Eur Respir J, 54 (1) 1802140; 10.1183/13993003.02140-2018
Year: 2019



The occupations at increased risk of COPD: analysis of lifetime job-histories in the population-based UK Biobank Cohort
Source: Eur Respir J, 54 (1) 1900186; 10.1183/13993003.00186-2019
Year: 2019



EXACTLE-Trial: Main results. How can EXACTLE help in AATD patients' treatment?
Source: Annual Congress 2008 - EXACTLE: EXAcerbations and CT scans as Lung Endpoints in Alpha-1-Antitrypsin Deficiency
Year: 2008